We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...

AbbVie Inc. closed 0.64% short of its 52-week high of $215.66, which the company reached on March 4th.

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie Inc. (NYSE:ABBV – Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $207.42 and ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE ... tend to measure success primarily by stock price appreciation, a deeper analysis offers a broader perspective.

This is an inherently challenging task. In one of the tables in the ABBV stock analysis, readers can see that Humira's revenue started rapidly decreasing since 2023 when the product lost its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie’s Cancer Deal With Xilio Therapeutics ... coli Vaccine Fails in Phase III Study An interim analysis of a phase III study on Sanofi and J&J’s vaccine candidate for extraintestinal ...

A separate analysis from T ... If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest ...